inflammation pain News
-
Panag Pharma Announces Patent Grant
Panag Pharma Inc., announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/722,991 Entitled: COMPOSITIONS AND METHODS FOR TREATMENT OF OCULAR INFLAMMATION AND/OR PAIN, a patent which protects its novel topical ocular product formulations. Panag Pharma’s ocular formulation leverages a novel drug platform ...
-
Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.
ARLINGTON, Mass., May 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has entered into a definitive agreement to sell its commercial portfolio and related intellectual property assets to Alcon Inc. ...
-
LayerBio CEO Presents OcuRing-K at OIS Anterior Innovation Showcase
Dr. Ken Mandell, Founder and CEO of LayerBio, presented an update on the development of its novel OcuRing-K ketorolac implant for treatment of postoperative pain and inflammation with cataract surgery. To see video, please click ...
-
Panag Pharma Announces Launch Of A Regional Pilot Program
Halifax, Nova Scotia. Panag Pharma hosted a seminar for Health Care Professionals and the launch of a Regional Pilot Program to introduce Topical AOTC, a new generation pain and inflammation product. Topical AOTC is a Health Canada approved natural product indicated for temporarily relief of aches and pains of muscles and joints associated with simple backache, lumbago, strains and sprains and ...
-
Panag Pharma announces health Canada License for a topical cold-sore formulation NPN 80084806
Halifax, Nova Scotia. Panag Pharma announces Health Canada approval for a topical Cold-Sore Formulation, a new generation topical formulation with a dual mechanism of action that improves healing rates and reduces symptoms, i.e. pain, associated with herpes labialis (cold sores). The topical Cold-Sore Formulation is a natural health product indicated for the relief of symptoms associated ...
-
Panag Pharma Announces Health Canada License for Topical A OTC (NPN 80070485)
Panag Pharma announces Health Canada approval for Topical AOTC, a new generation topical formulation with a dual mechanism of action against pain. Topical AOTC is a natural health product indicated for temporarily relief of aches and pains of muscles and joints associated with simple backache, lumbago, strains and sprains and arthritis. Topical AOTC uses a novel technology targeting the ...
-
Sight Sciences Receives FDA 510(k) Clearance of the TearCare System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the TearCare® System for the treatment of meibomian gland dysfunction (MGD), the leading cause of dry eye disease (DED). The indication ...
-
Showcase
Improve Your Wellbeing with Remedial Massage in Hobart City: How to Find the Right Therapist
Welcome to the definitive resource to improving your wellbeing with remedial massage in Hobart City! If you want to eliminate stress, ease tension, and improve your overall health, you’ve come to the correct place. In this blog post, we’ll look at the many benefits of remedial massage and offer helpful advice on how to select the right therapist for you. So sit back, relax, and ...
-
Panag Pharma announces licensing agreement with Tetra Bio Pharma
Halifax, Nova Scotia. Panag Pharma Inc. announces that it has entered into a licensing agreement with Tetra Bio Pharma for its Topical ARx and Ocular products. The Licensing Agreement provides for the continued development and commercialization of Panag’s unique products focused on providing patients with effective relief from pain. Dr. Cheliak, Panag’s CEO notes that ...
-
CBD For Beginners: Everything you should Know About Cannabidiol
CBD For Beginners: Everything You Should Know About Cannabidiol You have likely already heard about the many potential benefits of including CBD in your wellness routine, but the idea of approaching CBD for beginners can be a little daunting. What is CBD? Is it addictive? How will it affect my body, and how is it consumed? For anyone just now considering CBD, there are tons of questions you may ...
By Medcbdx
-
HTI announces Dr. Doug Kawahara as Senior Advisor for AI/ML Drug Discovery
Health Technology Innovations, Inc. (HTI) is excited to announce that Dr. Doug Kawahara is joining HTI as Senior Advisor for AI/ML in Drug Discovery. Dr. Kawahara brings extensive experience in drug discovery and development to HTI. He is currently President & CEO of Elex Biotech (Portland, OR), a company developing novel drugs for the treatment of arrhythmia and heart failure. Previously, ...
-
Tetra Bio-Pharma Announces Closing of $2.1 Million Marketed Public Offering of Units
OTTAWA, ON, Dec. 21, 2021 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the closing of its marketed public offering (the "Offering") of 13,064,000 units of the Company (the "Units"), at a price of $0.163 per Unit for aggregate gross proceeds of $2.1 ...
-
Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology
Panag Pharma Inc (Panag), a subsidiary of Tetra Bio-Pharma, will collect royalties on sales on products produced with the technology True North has licensed from Panag. Use of a highly innovative proprietary liposome encapsulated technology leads to a better CBD absorption. This New True North Nectar product line in liquid and powder formats are expected to launch in select markets in Q4 ...
-
Lilly`s Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study
Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3 induction study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderate to severe ulcerative colitis (UC). LUCENT-2, a multicenter, randomized, double-blind, placebo-controlled maintenance study of mirikizumab in ...
-
Feldan Therapeutics forms A Scientific Advisory Board and Expands Its Leadership Team
Feldan Therapeutics, a biotechnology company focusing on the development of therapeutics based on the intracellular delivery of proteins and peptides, announces the creation of a scientific advisory board and the appointment of an Acting Vice-President, Drug Development. “I am glad to welcome a group of highly experienced scientists having extensive clinical development and executive ...
-
CBD May Slow Cancer Growth
According to the American Cancer Society, scientists have recently reported that THC and other cannabinoids such as CBD slow growth and/or cause death in certain types of cancer cells growing in lab dishes. This is not only fascinating, but encouraging news for not only researchers, but those who are diagnosed with cancer, or have a loved one who has cancer. Additionally, some animal studies ...
-
QIXLEEF™ Aerosol Meets the Criteria Established by the U.S. FDA for Delivery of Inhalation Aerosols
Tetra Bio-Pharma Confirms Meeting with the FDA to Align on the Requirements for Marketing Authorization OTTAWA, ON, Nov. 29, 2021 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced that it received a letter from the United States Food and Drug Administration (FDA), ...
-
U.S. Nationwide Commercial Availability of the VenSure Balloon Sinus Dilation System and Cube Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S. nationwide commercial availability of the VenSure™ Balloon Sinus Dilation System and Cube™4D Navigation System with VirtuEye™ photo registration. The VenSure Balloon and Cube 4D Navigation Systems ...
-
How Often should you Take CBD?
How Often Should You Take CBD? How often should you take CBD? It’s a fairly common question, and although more research still needs to be conducted to get a better idea, we know that it’s perfectly safe to take CBD every day. CBD is a non-psychoactive cannabinoid harvested from the industrial hemp plant and has been known to assist in a variety of functions. So long as you stay ...
By Medcbdx
-
Panag Pharma Inc. Announces Initiation Of A Clinical Trial
Halifax, Nova Scotia. Panag Pharma, Inc. launched a clinical trial evaluating the use of the newly NHP registered product Topical AOTC, a new generation topical for pain and pain associated with inflammation. Topical AOTC is a Health Canada approved natural health product indicated for temporary relief of aches and pains of muscles and joints associated with simple backache, lumbago, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you